Your browser doesn't support javascript.
loading
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany.
Krebs, Markus; Haller, Florian; Spörl, Silvia; Gerhard-Hartmann, Elena; Utpatel, Kirsten; Maurus, Katja; Kunzmann, Volker; Chatterjee, Manik; Venkataramani, Vivek; Maatouk, Imad; Bittrich, Max; Einwag, Tatjana; Meidenbauer, Norbert; Tögel, Lars; Hirsch, Daniela; Dietmaier, Wolfgang; Keil, Felix; Scheiter, Alexander; Immel, Alexander; Heudobler, Daniel; Einhell, Sabine; Kaiser, Ulrich; Sedlmeier, Anja M; Maurer, Julia; Schenkirsch, Gerhard; Jordan, Frank; Schmutz, Maximilian; Dintner, Sebastian; Rosenwald, Andreas; Hartmann, Arndt; Evert, Matthias; Märkl, Bruno; Bargou, Ralf; Mackensen, Andreas; Beckmann, Matthias W; Pukrop, Tobias; Herr, Wolfgang; Einsele, Hermann; Trepel, Martin; Goebeler, Maria-Elisabeth; Claus, Rainer; Kerscher, Alexander; Lüke, Florian.
  • Krebs M; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Department of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany. Electronic address: krebs_m@ukw.de.
  • Haller F; Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Spörl S; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; Department of Medicine V, Hematology and Oncology, University Hospital Erlangen, 91054 Erlangen, Germany.
  • Gerhard-Hartmann E; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
  • Utpatel K; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Maurus K; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
  • Kunzmann V; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Chatterjee M; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Venkataramani V; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Maatouk I; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Bittrich M; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Einwag T; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Meidenbauer N; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; Department of Medicine V, Hematology and Oncology, University Hospital Erlangen, 91054 Erlangen, Germany.
  • Tögel L; Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Hirsch D; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Dietmaier W; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Keil F; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Scheiter A; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Immel A; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Heudobler D; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Einhell S; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Kaiser U; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Sedlmeier AM; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Maurer J; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Schenkirsch G; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany.
  • Jordan F; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Department of Hematology and Clinical Oncology, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Schmutz M; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Department of Hematology and Clinical Oncology, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany; Institute of Digital Medicine (IDM), Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Dintner S; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Institute of Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Rosenwald A; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Institute of Pathology, University of Würzburg, 97080 Würzburg, Germany.
  • Hartmann A; Institute of Pathology, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, 91054 Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany.
  • Evert M; Institute of Pathology, University of Regensburg, 93053 Regensburg, Germany; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany.
  • Märkl B; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Institute of Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Bargou R; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany.
  • Mackensen A; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; Department of Medicine V, Hematology and Oncology, University Hospital Erlangen, 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany.
  • Beckmann MW; Comprehensive Cancer Center Erlangen-EMN, 91054 Erlangen, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany; Department of Gynecology and Obstetrics, University Hospital Erlangen, 91054 Erlangen, Germany.
  • Pukrop T; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany; Division of Personalized Tumor Therapy, Fraunhof
  • Herr W; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Einsele H; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany.
  • Trepel M; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Department of Hematology and Clinical Oncology, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany; Bavarian Cancer Research Center (BZKF), 91052 Erlangen, Germany.
  • Goebeler ME; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany; Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Claus R; Comprehensive Cancer Center Augsburg, 86156 Augsburg, Germany; Department of Hematology and Clinical Oncology, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany; Institute of Pathology and Molecular Diagnostics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Kerscher A; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, 97080 Würzburg, Germany.
  • Lüke F; Comprehensive Cancer Center Ostbayern, 93053 Regensburg, Germany; Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, 93053 Regensburg, Germany; Division of Personalized Tumor Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053 Rege
Eur J Cancer ; 207: 114144, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38852290
ABSTRACT

PURPOSE:

Providing patient access to precision oncology (PO) is a major challenge of clinical oncologists. Here, we provide an easily transferable model from strategic management science to assess the outreach of a cancer center.

METHODS:

As members of the German WERA alliance, the cancer centers in Würzburg, Erlangen, Regensburg and Augsburg merged care data regarding their geographical impact. Specifically, we examined the provenance of patients from WERA´s molecular tumor boards (MTBs) between 2020 and 2022 (n = 2243). As second dimension, we added the provenance of patients receiving general cancer care by WERA. Clustering our catchment area along these two dimensions set up a four-quadrant matrix consisting of postal code areas with referrals towards WERA. These areas were re-identified on a map of the Federal State of Bavaria.

RESULTS:

The WERA matrix overlooked an active screening area of 821 postal code areas - representing about 50 % of Bavaria´s spatial expansion and more than six million inhabitants. The WERA matrix identified regions successfully connected to our outreach structures in terms of subsidiarity - with general cancer care mainly performed locally but PO performed in collaboration with WERA. We also detected postal code areas with a potential PO backlog - characterized by high levels of cancer care performed by WERA and low levels or no MTB representation.

CONCLUSIONS:

The WERA matrix provided a transparent portfolio of postal code areas, which helped assessing the geographical impact of our PO program. We believe that its intuitive principle can easily be transferred to other cancer centers.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicina de Precisión / Accesibilidad a los Servicios de Salud / Oncología Médica / Neoplasias Límite: Humans País como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Medicina de Precisión / Accesibilidad a los Servicios de Salud / Oncología Médica / Neoplasias Límite: Humans País como asunto: Europa Idioma: En Año: 2024 Tipo del documento: Article